Literature DB >> 29733710

Generic Price Competition For Specialty Drugs: Too Little, Too Late?

Ashley L Cole1, Stacie B Dusetzina2.   

Abstract

The case of generic imatinib demonstrates several potential barriers to effective generic price competition for specialty prescription drugs, including fewer market entrants, smaller-than-expected price reductions, shifts in prescribing toward more expensive brand-name treatments, and limited uptake of the generic product.

Entities:  

Keywords:  Access To Care; Cost of Health Care; Health Spending; Pharmaceuticals

Mesh：

Substances：

Year:  2018        PMID： 29733710     DOI： 10.1377/hlthaff.2017.1684

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN： 0278-2715            Impact factor:   6.301


  11 in total

Review 1.  Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment.

Authors:  Scott F Huntington
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

2.  Expenditures for First- and Second-Generation Tyrosine Kinase Inhibitors Before and After Transition of Imatinib to Generic Status.

Authors:  Kelly M Kenzik; Ravi Bhatia; Smita Bhatia
Journal:  JAMA Oncol       Date:  2020-04-01       Impact factor: 31.777

3.  Long-Term Patterns of Oral Anticancer Agent Adoption, Duration, and Switching in Patients With CML.

Authors:  Matthew P Banegas; Donna R Rivera; Maureen C O'Keeffe-Rosetti; Nikki M Carroll; Pamala A Pawloski; David C Tabano; Mara M Epstein; Kai Yeung; Mark C Hornbrook; Christine Lu; Debra P Ritzwoller
Journal:  J Natl Compr Canc Netw       Date:  2019-10-01       Impact factor: 11.908

4.  Health Care Cost Associated With Contemporary Chronic Myelogenous Leukemia Therapy Compared With That of Other Hematologic Malignancies.

Authors:  Jennifer J Wilkes; Gary H Lyman; David R Doody; Shasank Chennupati; Laura K Becker; Pamela E Morin; Lena E Winestone; Henry J Henk; Eric J Chow
Journal:  JCO Oncol Pract       Date:  2020-08-21

5.  Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.

Authors:  VÉronique C Raimond; William B Feldman; Benjamin N Rome; Aaron S Kesselheim
Journal:  Milbank Q       Date:  2021-03       Impact factor: 6.237

6.  Beyond the cost-effectiveness acceptability curve: The appropriateness of rank probabilities for presenting the results of economic evaluation in multiple technology appraisal.

Authors:  David Epstein
Journal:  Health Econ       Date:  2019-05-02       Impact factor: 3.046

7.  Factors Associated With Prescriptions for Branded Medications in the Medicare Part D Program.

Authors:  Mariana P Socal; Ge Bai; Gerard F Anderson
Journal:  JAMA Netw Open       Date:  2021-03-01

8.  Trends in Prices of Drugs Used to Treat Metastatic Non-Small Cell Lung Cancer in the US From 2015 to 2020.

Authors:  Aakash Desai; Caleb Scheckel; Chelsee J Jensen; Jacob Orme; Colt Williams; Nilay Shah; Konstantinos Leventakos; Alex A Adjei
Journal:  JAMA Netw Open       Date:  2022-01-04

9.  An Optimal Control Framework for the Automated Design of Personalized Cancer Treatments.

Authors:  Fabrizio Angaroni; Alex Graudenzi; Marco Rossignolo; Davide Maspero; Tommaso Calarco; Rocco Piazza; Simone Montangero; Marco Antoniotti
Journal:  Front Bioeng Biotechnol       Date:  2020-05-28

Review 10.  Unlocking Access To Novel Medicines In China-A Review From A Health System Perspective.

Authors:  Yifan Diao; Mingshuang Li; Zhiran Huang; Jing Sun; Yoke Ling Chee; Yunali Liu
Journal:  Risk Manag Healthc Policy       Date:  2019-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.